Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D L Wallace

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Gynecologic Oncology|December 1, 1990
A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group studyG R Weiss, S Green, E V Hannigan, et al.
European Journal of Immunology|February 12, 2000
CD7 expression distinguishes subsets of CD4(+) T cells with distinct functional properties and ability to support replication of HIV-1D L Wallace, P M Matear, D C Davies, et al.
Gynecologic Oncology|June 1, 1990
A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trialG R Weiss, S Green, E V Hannigan, et al.
European Journal of Immunology|January 1, 1985
Investigation of early T cell activation: analysis of the effect of specific antigen, interleukin 2 and monoclonal antibodies on intracellular free calcium concentrationK O'Flynn, E D Zanders, J R Lamb, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 9, 2001
The exon A (C77G) mutation is a common cause of abnormal CD45 splicing in humansE Z Tchilian, D L Wallace, N Imami, et al.
Immunology|November 1, 1996
Fibroblasts prevent apoptosis of IL-2-deprived T cells without inducing proliferation: a selective effect on Bcl-XL expressionW Gombert, N J Borthwick, D L Wallace, et al.
Gynecologic Oncology|June 1, 1996
Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology GroupF M Muggia, P Y Liu, D S Alberts, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Gynecologic Oncology|December 1, 1990
A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group studyG R Weiss, S Green, E V Hannigan, et al.
European Journal of Immunology|February 12, 2000
CD7 expression distinguishes subsets of CD4(+) T cells with distinct functional properties and ability to support replication of HIV-1D L Wallace, P M Matear, D C Davies, et al.
Gynecologic Oncology|June 1, 1990
A phase II trial of cisplatin and 5-fluorouracil with allopurinol for recurrent or metastatic carcinoma of the uterine cervix: a Southwest Oncology Group trialG R Weiss, S Green, E V Hannigan, et al.
European Journal of Immunology|January 1, 1985
Investigation of early T cell activation: analysis of the effect of specific antigen, interleukin 2 and monoclonal antibodies on intracellular free calcium concentrationK O'Flynn, E D Zanders, J R Lamb, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 9, 2001
The exon A (C77G) mutation is a common cause of abnormal CD45 splicing in humansE Z Tchilian, D L Wallace, N Imami, et al.
Immunology|November 1, 1996
Fibroblasts prevent apoptosis of IL-2-deprived T cells without inducing proliferation: a selective effect on Bcl-XL expressionW Gombert, N J Borthwick, D L Wallace, et al.
Gynecologic Oncology|June 1, 1996
Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology GroupF M Muggia, P Y Liu, D S Alberts, et al.
Pageof 3